# A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer

> **NCT02428270** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 16 (actual)

## Conditions studied

- Pancreatic Cancer
- Adenocarcinoma

## Interventions

- **DRUG:** GSK2256098
- **DRUG:** Trametinib

## Key facts

- **NCT ID:** NCT02428270
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-06
- **Final completion:** 2022-10-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-11-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02428270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02428270, "A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02428270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*